^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Elrexfio (elranatamab-bcmm)

    i
    Other names: PF-06863135, PF 06863135, PF06863135, PF‑3135, PF3135, RN 613, RN613, RN-613
    Company:
    Pfizer
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    Apply
    Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes (NCT06282978)
    Phase 2
    PETHEMA Foundation
    Recruiting
    Last update posted :
    03/06/2024
    Initiation :
    11/23/2023
    Primary completion :
    05/01/2025
    Completion :
    12/01/2029
    KIT • CD19 • CD38 • PTPRC • NCAM1 • CD27 • CD81
    |
    CD38 expression • CD19 expression • NCAM1 expression • CD27 expression • CD5 overexpression • NCAM1 overexpression
    |
    Elrexfio (elranatamab-bcmm)